Autoimmune Hepatitis: Disease Overview

Autoimmune hepatitis (AIH) is a chronic, progressive inflammatory liver disease characterized by immune-mediated destruction of hepatocytes. Left untreated, AIH leads to progressive fibrosis, cirrhosis, and liver failure. With appropriate immunosuppressive therapy, however, the majority of patients achieve remission and have excellent long-term survival. The central challenge in AIH management is not treatment but diagnosis: AIH has no single pathognomonic feature, and its clinical, serological, and histological findings overlap substantially with other liver diseases, including viral hepatitis, drug-induced liver injury (DILI), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and Wilson disease.

The disease was first described in 1950 by the Swedish physician Jan Waldenström, who reported a series of young women with chronic hepatitis, marked hypergammaglobulinaemia, and amenorrhea. Over subsequent decades, the autoimmune nature of the disease was established through the identification of circulating autoantibodies, the association with other autoimmune conditions, the presence of characteristic histological features (interface hepatitis with lymphoplasmacytic infiltration), and the dramatic response to corticosteroid therapy.

AIH affects all ages, ethnicities, and both sexes, though it has a marked female predominance (approximately 3:1 to 4:1 female-to-male ratio). It has a bimodal age distribution, with peaks in childhood/adolescence and in the fourth to sixth decades of life. The prevalence varies by geography and ethnicity; estimates range from 10 to 25 per 100,000 in European and North American populations. The disease may present acutely (sometimes mimicking acute viral hepatitis or even fulminant hepatic failure) or insidiously with fatigue, arthralgias, and incidentally discovered transaminase elevations.

The Diagnostic Challenge and the Need for Scoring Systems

Unlike many liver diseases, AIH cannot be diagnosed by a single test. There is no biomarker or histological finding that is both highly sensitive and highly specific. Autoantibodies (ANA, SMA, LKM-1) are present in the majority of patients but also occur in other liver diseases and even in healthy individuals at low titers. Elevated immunoglobulin G (IgG) is a hallmark but is not universal, particularly early in the disease course. Interface hepatitis on liver biopsy is characteristic but also occurs in chronic viral hepatitis and DILI. The diagnosis therefore requires a composite assessment integrating clinical features, laboratory findings, autoantibody profiles, histological patterns, and the exclusion of alternative diagnoses.

This diagnostic complexity motivated the International Autoimmune Hepatitis Group (IAIHG) to develop a standardized scoring system. The IAIHG, founded in 1992, is a multinational consortium of hepatologists dedicated to establishing uniform diagnostic criteria for AIH to facilitate clinical research and improve diagnostic consistency across institutions.

Historical Development: From the 1993 Criteria to the 1999 Revision

The original IAIHG scoring system was published in 1993 by Johnson and McFarlane. It was the first comprehensive, points-based diagnostic tool for AIH, incorporating clinical, biochemical, serological, histological, and treatment-response parameters. The system was designed primarily for research purposes: to ensure that patients enrolled in clinical trials of AIH met a uniform diagnostic standard. It assigned positive points to features supporting an AIH diagnosis and negative points to features suggesting alternative diagnoses, producing a composite score that classified patients as "definite" or "probable" AIH.

Although widely adopted, the 1993 criteria had several recognized limitations. The point assignments for certain parameters were considered suboptimal based on accumulating clinical experience. The scoring of the alkaline phosphatase (ALP) to aminotransferase ratio, the drug history assessment, the histological composite, and the treatment response categories all required refinement. Additionally, the growing recognition of seronegative AIH (patients with typical clinical and histological features but negative standard autoantibodies) and the availability of additional autoantibody tests and HLA typing necessitated an update.

In 1999, the IAIHG published the Revised Original Scoring System, led by Alvarez and colleagues, in the Journal of Hepatology. This revision maintained the overall structure of the 1993 system but updated point assignments for several parameters, modified the histological scoring composite, added optional parameters for seronegative patients, and refined the treatment response scoring. The revised system evaluates 13 core parameters and 2 optional parameters (applicable only in seronegative patients), producing a total score with separate diagnostic cutoffs for pre-treatment and post-treatment interpretation.

Scoring Parameters: Detailed Analysis

1. Sex (0 to +2 points)

Female sex receives +2 points; male sex receives 0 points. This reflects the strong female predominance of AIH (3:1 to 4:1 female-to-male ratio across most populations). The female predisposition is thought to be related to hormonal influences on immune regulation and X-chromosome-linked immune response genes. While AIH certainly occurs in males, the scoring system uses female sex as a positive diagnostic feature because it increases the prior probability of the diagnosis in the appropriate clinical context.

This parameter has been criticized as introducing sex-based bias into the diagnostic algorithm: a male patient and a female patient with otherwise identical clinical features will receive different scores, potentially leading to underdiagnosis in males. Clinicians should be aware that male patients with otherwise strong features of AIH should not be dismissed on the basis of a lower composite score. In practice, the 2-point differential is unlikely to change diagnostic classification by itself, but it does highlight the importance of maintaining a high index of suspicion regardless of sex.

2. ALP:AST (or ALP:ALT) Ratio (-2 to +2 points)

This ratio distinguishes hepatocellular-predominant liver injury (favoring AIH) from cholestatic-predominant injury (favoring PBC, PSC, or drug-induced cholestasis). The scoring is:

• <1.5: +2 points. A low ratio indicates that aminotransferase elevation predominates over alkaline phosphatase elevation, a pattern consistent with hepatocellular injury and supportive of AIH.
• 1.5 to 3.0: 0 points. A neutral ratio that does not strongly favor either hepatocellular or cholestatic disease.
• >3.0: -2 points. A high ratio indicates cholestatic predominance, raising concern for PBC, PSC, or other cholestatic conditions.

The original 1999 publication does not specify whether to use AST or ALT in the denominator. In practice, clinicians use whichever aminotransferase produces the more clinically informative ratio. ALT is generally considered more liver-specific than AST. Some authors recommend using the ratio that is most favorable to the patient (i.e., the lower of the two ratios) to avoid missing a diagnosis.

It is important to note that some patients with AIH, particularly those with overlap syndromes (AIH-PBC or AIH-PSC), may present with a mixed hepatocellular-cholestatic pattern that produces an intermediate or high ratio. The scoring penalty in these cases may lower the composite score below the diagnostic threshold, potentially leading to underdiagnosis of the autoimmune component.

3. Serum Globulins or IgG (0 to +3 points)

Polyclonal hypergammaglobulinaemia, predominantly IgG elevation, is one of the hallmarks of AIH. The scoring system uses the ratio of the patient's serum globulin (or IgG) level to the upper limit of normal (ULN) for the laboratory:

• >2.0 x ULN: +3 points
• 1.5 to 2.0 x ULN: +2 points
• 1.0 to 1.5 x ULN: +1 point
• <1.0 x ULN: 0 points

IgG elevation is present in approximately 85% of AIH patients at diagnosis. The degree of elevation correlates with disease activity and is a useful marker for monitoring treatment response. Markedly elevated IgG (>2 x ULN) is particularly suggestive of AIH and carries the maximum point assignment.

However, IgG can also be elevated in chronic viral hepatitis (typically to a lesser degree), liver cirrhosis from any cause, and other autoimmune conditions. Conversely, approximately 15% of AIH patients have normal IgG at presentation, particularly in acute-onset disease, early-stage disease, or certain demographic groups. Normal IgG does not exclude AIH.

When possible, IgG should be measured directly rather than inferred from the total protein minus albumin calculation, as the latter is less accurate. IgG subclass measurement is not part of the standard AIH workup but may occasionally provide additional information in atypical cases.

4. ANA, SMA, or LKM-1 Autoantibodies (0 to +3 points)

The three "conventional" autoantibodies associated with AIH are antinuclear antibody (ANA), smooth muscle antibody (SMA), and liver/kidney microsomal type 1 antibody (LKM-1). Their titers, measured by indirect immunofluorescence (IIF) on rodent tissue substrate, are scored as follows:

• >1:80: +3 points
• 1:80: +2 points
• 1:40: +1 point
• <1:40: 0 points

The highest titer among the three antibodies determines the score. ANA and SMA (particularly anti-actin SMA) are the characteristic markers of type 1 AIH, the most common form worldwide. LKM-1 is the hallmark of type 2 AIH, which is more common in children and in Southern European populations.

A critical consideration is the method of autoantibody detection. The scoring system was developed using IIF on rodent tissue substrate, which produces titer-based results (1:40, 1:80, etc.). Many modern laboratories use ELISA or multiplex bead assays, which report results in units or as positive/negative without true titer equivalence. Direct comparison between ELISA results and IIF titers is problematic, and clinicians should exercise caution when applying IIF-based titer cutoffs to non-IIF assay results. When the scoring system is being applied formally, IIF testing is preferred.

Low-titer autoantibodies (1:40 or below) are common in the general population and in patients with other liver diseases, particularly chronic hepatitis C. High-titer autoantibodies (>1:80) are much more specific for AIH but are not sufficient alone for diagnosis. Conversely, approximately 10 to 20% of AIH patients are seronegative for all three conventional antibodies, a group addressed by the optional seronegative parameters (discussed below).

5. Hepatitis Viral Markers (-3 to +3 points)

This parameter evaluates serological and molecular markers for hepatitis A, B, and C. The markers typically assessed include IgM anti-HAV, HBsAg, IgM anti-HBc, anti-HCV, and HCV-RNA. The scoring is binary:

• All negative: +3 points. The absence of viral hepatitis markers supports an AIH diagnosis by excluding the most common causes of chronic hepatitis worldwide.
• Any positive: -3 points. Positive viral markers indicate active or recent viral hepatitis, which is a competing diagnosis. The 6-point swing (from +3 to -3) reflects the critical importance of viral exclusion in the AIH diagnostic workup.

It is worth noting that viral hepatitis and AIH can coexist. Hepatitis C, in particular, can trigger autoimmune phenomena (including low-titer ANA and SMA positivity and even interface hepatitis on biopsy), creating diagnostic confusion. Patients with chronic hepatitis C who also have features of AIH may have true overlap or may have autoimmune features triggered by the viral infection. In such cases, the 3-point penalty for positive viral markers may be appropriate, but clinical judgment and expert consultation are essential.

6. Hepatotoxic Drug History (-4 to +1 points)

Recent or current use of medications known to cause hepatotoxicity carries a substantial penalty:

• No hepatotoxic drug exposure: +1 point
• Yes, hepatotoxic drug exposure: -4 points

The -4 point penalty is one of the largest single-parameter deductions in the scoring system, reflecting the importance of excluding drug-induced liver injury (DILI) as an alternative diagnosis. DILI can mimic AIH clinically, serologically, and histologically. Certain medications, including minocycline, nitrofurantoin, methyldopa, diclofenac, statins, and some herbal supplements, can produce an autoimmune-like hepatitis with positive autoantibodies, elevated IgG, and interface hepatitis on biopsy. This entity, sometimes called "drug-induced autoimmune-like hepatitis" or "DILI with autoimmune features," typically resolves after drug withdrawal, distinguishing it from true AIH, which relapses without ongoing immunosuppression.

The drug history assessment should be thorough, including prescription medications, over-the-counter drugs, herbal and dietary supplements, and recreational substances. The temporal relationship between drug exposure and the onset of liver injury is a critical diagnostic consideration.

7. Alcohol Intake (-2 to +2 points)

Average daily alcohol consumption is scored in three tiers:

• <25 g/day: +2 points. Low alcohol intake makes alcohol-related liver disease unlikely as a competing diagnosis.
• 25 to 60 g/day: 0 points. Moderate intake is diagnostically neutral.
• >60 g/day: -2 points. Heavy alcohol intake raises the possibility that the liver injury is wholly or partially attributable to alcohol.

For reference, a standard alcoholic drink in the United States contains approximately 14 grams of alcohol. Thus, <25 g/day corresponds to roughly less than 2 standard drinks, while >60 g/day corresponds to more than 4 standard drinks. The thresholds used in the scoring system align with the levels at which alcohol-related liver injury becomes increasingly likely.

Alcohol-related liver disease and AIH can coexist. Alcoholic hepatitis on biopsy typically shows steatosis, Mallory-Denk bodies, and neutrophilic infiltration, which differ from the lymphoplasmacytic interface hepatitis of AIH. However, overlap can occur, and some patients may have both conditions contributing to their liver injury. The alcohol intake score is intended to flag this possibility rather than to definitively exclude AIH.

8-12. Liver Histology (Composite: -11 to +5 points)

The histological assessment is one of the most complex and consequential components of the scoring system. It evaluates five features, three positive and two negative, plus a penalty rule:

Positive features:

• Interface hepatitis: +3 points if present. Interface hepatitis (formerly called "piecemeal necrosis") is the hallmark histological feature of AIH. It consists of lymphocyte- and plasma cell-mediated destruction of hepatocytes at the junction of the portal tract and the liver parenchyma, with disruption of the limiting plate. While not pathognomonic (it also occurs in chronic viral hepatitis and DILI), interface hepatitis is present in the vast majority of AIH cases and its absence should prompt reconsideration of the diagnosis.
• Lymphoplasmacytic infiltrate: +1 point if predominantly present. The inflammatory infiltrate in AIH is characteristically rich in lymphocytes and plasma cells. This pattern, while typical of AIH, must be distinguished from the predominantly lymphocytic (without prominent plasma cells) infiltrate of chronic viral hepatitis and the mixed inflammatory infiltrate of DILI.
• Rosetting of liver cells: +1 point if present. Hepatocyte rosetting refers to the arrangement of swollen hepatocytes in a rosette-like pattern around a central lumen, reflecting regenerative activity at the interface. It is a relatively specific but not highly sensitive feature of AIH.

Penalty for absence of positive features:

If none of the three positive histological features (interface hepatitis, lymphoplasmacytic infiltrate, rosetting) is present, a penalty of -5 points is applied. This is a critically important scoring rule. A liver biopsy that shows no evidence of interface hepatitis, no predominant lymphoplasmacytic infiltrate, and no rosetting is histologically inconsistent with AIH, and the 5-point penalty substantially reduces the likelihood of a definite or probable classification. This rule reinforces the importance of liver biopsy in the AIH diagnostic workup and discourages diagnosis without histological support.

Negative features:

• Biliary changes: -3 points if present. Histological features suggestive of bile duct injury (florid duct lesions, ductopenia, granulomatous cholangitis) raise concern for PBC or PSC rather than AIH. Their presence argues against a pure AIH diagnosis.
• Other changes suggesting a different etiology: -3 points if present. Histological features such as steatohepatitis (suggesting NAFLD/NASH or alcohol), copper-associated protein deposition (suggesting Wilson disease), iron overload (suggesting hemochromatosis), or granulomas (suggesting sarcoidosis or drug reaction) point toward alternative diagnoses.

The histological composite can range from -11 (no positive features [-5 penalty], plus biliary changes [-3], plus other changes [-3]) to +5 (all three positive features present, no negative features). This 16-point range makes histology one of the most influential components of the total score and underscores the central role of liver biopsy in the diagnostic algorithm.

13. Other Autoimmune Disease(s) (0 to +2 points)

The presence of another autoimmune disease in the patient or in a first-degree relative adds +2 points. AIH frequently coexists with other autoimmune conditions, including autoimmune thyroiditis (Hashimoto's or Graves' disease), type 1 diabetes mellitus, celiac disease, inflammatory bowel disease, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus. A personal or family history of autoimmune disease increases the prior probability of AIH and supports the concept of shared autoimmune susceptibility.

The concurrence of AIH with other autoimmune conditions is estimated at 20 to 40% in various series. Autoimmune thyroid disease is the most common concurrent condition. Clinicians should specifically inquire about personal and family autoimmune history when evaluating a patient for possible AIH.

14. Optional Parameters for Seronegative Patients (0 to +3 points)

When the conventional autoantibodies (ANA, SMA, LKM-1) are all negative or below 1:40, two additional parameters can be scored:

Positivity for other defined autoantibodies (+2 points):

Several "non-standard" autoantibodies have been identified in AIH patients and may be positive when conventional markers are absent. These include:

• pANCA (perinuclear anti-neutrophil cytoplasmic antibody): Present in up to 90% of type 1 AIH patients. In AIH, the target antigen is often distinct from the myeloperoxidase (MPO) target in vasculitis, and the pattern is sometimes described as "atypical pANCA" or "anti-neutrophil nuclear antibody."
• Anti-SLA/LP (soluble liver antigen/liver-pancreas antibody): Highly specific for AIH (approaching 100% specificity). Present in approximately 10 to 30% of AIH patients. Some authorities consider anti-SLA positivity sufficient to diagnose AIH even in the absence of other autoantibodies.
• Anti-LC1 (liver cytosol type 1 antibody): Associated with type 2 AIH, sometimes positive when LKM-1 is negative.
• Anti-ASGPR (asialoglycoprotein receptor antibody): Present in 60 to 80% of AIH patients, correlates with disease activity.
• Anti-sulfatide antibodies: Less commonly tested but reported in some AIH cohorts.

Positivity for any of these defined autoantibodies in a seronegative patient provides serological support for an AIH diagnosis and receives +2 points.

HLA-DR3 or HLA-DR4 (+1 point):

The strongest genetic associations with type 1 AIH in Caucasian populations are the HLA class II alleles DRB1*03:01 (DR3) and DRB1*04:01 (DR4). These alleles are found in approximately 50 to 80% of type 1 AIH patients in European and North American populations. HLA-DR3 is associated with younger age at onset, more aggressive disease, and lower rates of treatment response, while HLA-DR4 is associated with older age at onset and a generally more favorable course. The presence of either allele in a seronegative patient provides immunogenetic support for an AIH diagnosis.

HLA typing is not routinely performed in the diagnostic workup of AIH but may be obtained in diagnostically challenging cases, particularly when conventional autoantibodies are absent. The +1 point assignment reflects its supportive but not definitive diagnostic role.

15. Response to Therapy (0 to +3 points)

The treatment response adds retrospective diagnostic evidence:

• Complete response: +2 points. Complete biochemical normalization (normal transaminases and IgG) with immunosuppressive therapy strongly supports an AIH diagnosis.
• Relapse: +3 points. Relapse after withdrawal of immunosuppression (or dose reduction) is even more diagnostic, as it demonstrates that the liver inflammation is immune-mediated and requires ongoing immunosuppression to control. Relapse carries the maximum therapy-related points because it is highly characteristic of AIH; few other liver diseases relapse in this pattern.
• Not applicable: 0 points. For patients who have not yet been treated or for whom treatment response cannot be assessed.

The inclusion of treatment response means that the scoring system can be applied both before and after a therapeutic trial. This is particularly useful in diagnostically uncertain cases where a corticosteroid trial may serve as both treatment and diagnostic test. A dramatic improvement in liver biochemistry with corticosteroids, followed by relapse upon withdrawal, provides compelling evidence for AIH and can push a "probable" pre-treatment score into the "definite" post-treatment category.

16. Anti-Mitochondrial Antibody (AMA) (-4 to 0 points)

AMA is the serological hallmark of primary biliary cholangitis (PBC), present in approximately 95% of PBC patients. AMA positivity in the context of possible AIH carries a substantial penalty of -4 points, reflecting the strong diagnostic weight of AMA for PBC rather than AIH.

Patients with both AMA positivity and features of AIH may have an overlap syndrome (AIH-PBC overlap), which occurs in approximately 5 to 10% of patients with either condition. The -4 penalty may cause the composite score to fall below the AIH diagnostic threshold in these patients, even when genuine autoimmune hepatitis is present. Clinicians should be aware of this limitation and consider overlap syndromes when AMA is positive in a patient with otherwise strong AIH features. The Paris criteria for AIH-PBC overlap provide a separate diagnostic framework for these cases.

Score Interpretation: Pre-Treatment and Post-Treatment Cutoffs

The revised scoring system provides separate diagnostic thresholds depending on whether the score is calculated before or after a therapeutic trial:

The post-treatment thresholds are higher because successful treatment response (+2 or +3 points) adds to the total score. The higher cutoffs compensate for this addition, maintaining diagnostic stringency.

A "definite" classification indicates that the composite evidence strongly supports an AIH diagnosis. A "probable" classification indicates that AIH is the most likely diagnosis but that some atypical features are present or some typical features are absent. A score below the "probable" threshold does not exclude AIH; rather, it indicates that the available evidence does not meet the standardized diagnostic criteria and that further investigation or alternative diagnoses should be considered.

Types of Autoimmune Hepatitis

AIH is classified into two types based on the autoantibody profile, with distinct clinical features and demographics:

Type 1 AIH

Type 1 AIH is defined by the presence of ANA and/or SMA (particularly anti-actin antibody). It accounts for approximately 80% of AIH cases in adults and is the most common type worldwide. Type 1 AIH affects all ages but has a peak incidence in middle-aged women. The disease is associated with HLA-DR3 and HLA-DR4 in Caucasian populations. pANCA is positive in the majority of type 1 AIH patients and can provide additional serological support, particularly in atypical cases.

Type 2 AIH

Type 2 AIH is defined by the presence of LKM-1 (directed against cytochrome P450 2D6) and/or anti-LC1. It accounts for approximately 20% of AIH cases overall but is proportionally more common in children and in Southern European populations. Type 2 AIH tends to present at a younger age, often in childhood or adolescence, and may have a more aggressive course with a higher frequency of acute presentation and progression to cirrhosis. It is associated with HLA-DR7 and HLA-DR3. Anti-LC1 may be the sole marker in some type 2 patients who are LKM-1 negative.

The revised scoring system does not distinguish between type 1 and type 2 AIH; both types are scored using the same parameters and cutoffs. The distinction between types is clinically relevant for prognosis and follow-up but does not affect the diagnostic algorithm.

The Revised Original Score Versus the Simplified IAIHG Score

In 2008, Hennes and colleagues published the Simplified Scoring System for AIH diagnosis, also under the auspices of the IAIHG. The simplified system evaluates only four parameters: autoantibody titer (ANA or SMA), IgG level, liver histology (compatible, typical, or atypical), and absence of viral hepatitis. It produces a score from 0 to 8, with a cutoff of 6 or above for "probable" AIH and 7 or above for "definite" AIH.

The two systems have different strengths and are best viewed as complementary rather than competing tools:

Czaja (2008) directly compared the two systems and found that the revised original score had higher sensitivity (100% vs. 95%) but lower specificity (73% vs. 90%) and lower positive predictive value (82% vs. 92%) compared with the simplified score. The revised original system's higher sensitivity makes it more useful for ensuring that true AIH cases are not missed, which is important in research settings. The simplified system's higher specificity makes it better at excluding AIH in patients with alternative diagnoses, which is valuable in routine clinical practice.

EASL (European Association for the Study of the Liver) and AASLD (American Association for the Study of Liver Diseases) guidelines recommend that both scoring systems can be used, with the simplified system generally preferred for initial clinical assessment and the revised original system reserved for diagnostically challenging cases, research, and situations where the simplified system yields equivocal results.

Overlap Syndromes

A significant proportion of patients with autoimmune liver disease do not fit neatly into a single diagnostic category. The major overlap syndromes relevant to AIH scoring are:

AIH-PBC Overlap

Approximately 5 to 10% of patients with PBC have concurrent features of AIH, and vice versa. These patients typically have AMA positivity (characteristic of PBC) alongside elevated transaminases, high-titer ANA/SMA, elevated IgG, and interface hepatitis (characteristic of AIH). The Paris criteria require at least two of three PBC features (ALP >2x ULN or GGT >5x ULN, AMA positivity, florid bile duct lesions) and at least two of three AIH features (ALT >5x ULN, IgG >2x ULN or positive SMA, moderate to severe interface hepatitis).

In the revised original scoring system, AIH-PBC overlap patients are penalized by the AMA positivity (-4 points) and potentially by biliary changes on biopsy (-3 points) and a high ALP ratio (-2 points). These penalties can push the composite score below the probable threshold, even when genuine AIH is present. Clinicians should be aware of this limitation and consider overlap syndrome criteria separately from the IAIHG score when both PBC and AIH features coexist.

AIH-PSC Overlap

AIH-PSC overlap is more common in children and young adults than in older patients. These patients have features of AIH on liver biopsy and serology alongside cholangiographic evidence of sclerosing cholangitis. The biliary changes on biopsy and the cholestatic biochemical pattern may lower the revised AIH score. Magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP) is essential for diagnosing the PSC component, as the IAIHG score does not incorporate cholangiographic findings.

Seronegative Autoimmune Hepatitis

Approximately 10 to 20% of patients with clinical, biochemical, and histological features consistent with AIH are seronegative for the conventional autoantibodies (ANA, SMA, LKM-1). Seronegative AIH is a recognized entity that responds to immunosuppressive therapy similarly to seropositive AIH, confirming its autoimmune nature.

The revised scoring system addresses seronegative AIH through two mechanisms. First, the optional parameters for seronegative patients (other defined autoantibodies [+2] and HLA-DR3/DR4 [+1]) allow up to 3 additional points that can partially compensate for the 0 points received from the standard autoantibody parameter. Second, the treatment response parameters (+2 for complete response, +3 for relapse) allow the post-treatment score to reach definite or probable thresholds even when pre-treatment serological evidence is limited.

In practice, seronegative AIH patients may score below the pre-treatment threshold but achieve a definite or probable classification on post-treatment recalculation after a successful corticosteroid trial. This underscores the value of recalculating the score after treatment in diagnostically uncertain cases.

Drug-Induced Autoimmune-Like Hepatitis

A clinically important mimic of AIH is drug-induced autoimmune-like hepatitis (DI-AILH). Certain medications can trigger a hepatitis that is indistinguishable from AIH by serological, biochemical, and histological criteria. Common offending agents include minocycline, nitrofurantoin, methyldopa, hydralazine, diclofenac, infliximab, and some statins. The clinical picture includes positive autoantibodies (ANA, SMA), elevated IgG, and interface hepatitis with lymphoplasmacytic infiltration on biopsy.

The key distinguishing feature is the temporal relationship with drug exposure and the clinical course after drug withdrawal. True DI-AILH typically resolves after discontinuation of the offending agent and does not require long-term immunosuppression. In contrast, true AIH relapses after withdrawal of immunosuppressive therapy. Some patients may have a hybrid scenario where a drug triggers genuine AIH in a genetically predisposed individual, resulting in a disease that persists even after drug withdrawal.

The revised scoring system addresses this overlap primarily through the hepatotoxic drug parameter (-4 points). This penalty significantly lowers the composite score when drug exposure is present, reducing the likelihood of a definite or probable AIH classification. However, the penalty does not guarantee correct classification, and clinical judgment remains essential.

Pediatric Considerations

AIH in children has distinct features that affect the application of the revised scoring system. Type 2 AIH is proportionally more common in children than in adults. Autoantibody titers may be lower in children, and the ESPGHAN (European Society for Paediatric Gastroenterology, Hepatology and Nutrition) hepatology committee has recommended that lower titer cutoffs (1:20 for ANA and SMA, 1:10 for LKM-1) may be appropriate in the pediatric age group. The adult-derived titer thresholds in the revised scoring system (with 1:40 as the minimum for 1 point) may underestimate autoantibody positivity in children, potentially leading to lower scores and underdiagnosis.

Additionally, the sex-based scoring (female +2, male 0) may have a smaller effect size in pediatric AIH, where the female predominance is less pronounced than in adult disease. Children are also less likely to have significant alcohol exposure, meaning that the alcohol intake parameter will almost always contribute +2 points in the pediatric population.

Despite these considerations, the revised scoring system has been widely applied in pediatric populations, and several validation studies have confirmed its utility in children, though with the caveat that sensitivity may be slightly lower than in adults when standard adult cutoffs are used. The simplified scoring system has also been validated in pediatric cohorts and may be more practical for initial screening in children.

The Role of Liver Biopsy

Liver biopsy occupies a central position in the revised scoring system. The histological composite can contribute up to +5 points (or as low as -11 points), making it the single most influential parameter category in the score. Beyond its contribution to the numerical score, liver biopsy provides critical diagnostic information that cannot be obtained from serological or biochemical testing alone: the pattern of inflammation (interface vs. lobular, lymphoplasmacytic vs. neutrophilic), the degree of fibrosis, the presence of biliary injury, and the identification of features suggesting alternative diagnoses (steatosis, iron deposition, copper accumulation, granulomas).

EASL guidelines recommend liver biopsy as part of the standard AIH diagnostic workup. While the diagnosis can sometimes be made without biopsy in patients with a very characteristic presentation (high-titer autoantibodies, markedly elevated IgG, typical biochemical pattern, no competing diagnosis), biopsy adds diagnostic confidence, informs the revised score, assesses fibrosis stage, and may reveal unexpected findings that alter management.

There are clinical situations in which biopsy is not feasible (severe coagulopathy, fulminant presentation, patient refusal). In these cases, the revised scoring system will have a diminished score due to the absence of histological data. If none of the three positive histological features can be assessed, the -5 penalty is not applied (as the assessment was not performed rather than negative), but the positive points from histology are also unavailable. This limitation should be documented when reporting the score, and the diagnosis may need to rely more heavily on serological and clinical features, the simplified scoring system, or a therapeutic trial.

Limitations of the Revised Original Scoring System

Complexity

The 13+ parameter system is cumbersome compared with the 4-parameter simplified score. Calculating the revised score requires knowledge of the specific point assignments for each criterion level, the histological penalty rule, and the seronegative optional parameters. This complexity limits its utility for rapid bedside assessment and makes errors in scoring more likely.

Designed for Research, Not Individual Diagnosis

The scoring system was developed primarily to standardize cohort definition for clinical research, not to make or exclude the diagnosis in individual patients. Its sensitivity and specificity, while useful at the population level, do not capture the full clinical nuance of individual cases. A patient with a score of 9 (one point below the "probable" threshold) may still have AIH, while a patient with a score of 16 ("definite" threshold) may have an alternative diagnosis that coincidentally produces several features of AIH.

Autoantibody Methodology Dependence

The titer-based scoring was derived using IIF on rodent tissue substrate. The increasing use of ELISA and multiplex assays in clinical laboratories introduces a methodological mismatch that can affect scoring accuracy. Direct equivalence between IIF titers and ELISA results cannot be assumed.

Underperformance in Overlap Syndromes

Patients with AIH-PBC or AIH-PSC overlap may score below the AIH diagnostic threshold due to penalties for AMA positivity, biliary changes, and cholestatic biochemistry. These patients require separate assessment using overlap syndrome criteria.

No Incorporation of Modern Biomarkers

The scoring system predates the identification of some newer biomarkers and diagnostic techniques. Anti-SLA/LP, which is the most specific autoantibody for AIH, is not included in the core scoring parameters (it can only contribute through the seronegative optional parameter). Elastography for fibrosis assessment, advanced imaging techniques, and molecular profiling are not incorporated.

Static Assessment

The scoring system captures a single time-point assessment. AIH is a dynamic disease; autoantibody titers, IgG levels, transaminases, and histological features all change over time and with treatment. Serial application of the score may provide useful trend information but is not part of the standard methodology.

Clinical Workflow: How to Apply the Score

For clinicians applying the revised scoring system, the following workflow ensures systematic and accurate scoring:

1. Establish the clinical context: Document the patient's sex, age, presenting symptoms, and duration of illness. Record any personal or family history of autoimmune disease.
2. Obtain laboratory studies: Complete liver biochemistry panel (AST, ALT, ALP, bilirubin, albumin), serum globulins and IgG, hepatitis viral serologies (IgM anti-HAV, HBsAg, IgM anti-HBc, anti-HCV, HCV-RNA), and autoantibodies (ANA, SMA, LKM-1 by IIF, plus AMA). If conventional autoantibodies are negative, consider testing for pANCA, anti-SLA/LP, anti-LC1, and, in selected cases, HLA typing.
3. Calculate the ALP:AST (or ALP:ALT) ratio: Use the aminotransferase that produces the more clinically relevant ratio.
4. Review drug and alcohol history: Systematically document all medications, supplements, and average daily alcohol intake.
5. Obtain liver biopsy (when feasible): Review with an experienced hepatopathologist. Document the presence or absence of interface hepatitis, lymphoplasmacytic infiltrate, rosetting, biliary changes, and other features suggesting an alternative etiology.
6. Assign points for each parameter: Sum all parameter scores to obtain the total.
7. Select the appropriate interpretation mode: Use pre-treatment cutoffs if the patient has not yet received immunosuppressive therapy. Use post-treatment cutoffs if a therapeutic trial has been completed and treatment response can be assessed.
8. Integrate with clinical judgment: The score is one component of the diagnostic assessment. Always consider the full clinical picture, including features not captured by the scoring system, before making treatment decisions.

Treatment Implications by Diagnostic Category

While the revised scoring system is a diagnostic tool rather than a treatment algorithm, its diagnostic categories have direct treatment implications:

Definite AIH

Patients meeting the definite AIH threshold should be offered immunosuppressive therapy. Standard first-line treatment consists of prednis(ol)one alone or in combination with azathioprine. The combination regimen allows lower corticosteroid doses and is preferred in most adults. Treatment goals include complete biochemical remission (normalization of transaminases and IgG) and histological remission. Most patients achieve remission within 6 to 12 months, but long-term maintenance therapy is required in the majority, as relapse rates exceed 80% after treatment withdrawal.

Probable AIH

Patients with probable AIH scores warrant further investigation and, in many cases, a therapeutic trial with corticosteroids. A dramatic improvement in liver biochemistry with immunosuppression provides additional diagnostic evidence and allows recalculation using the post-treatment cutoffs. Some patients in the probable category will be reclassified as definite AIH after treatment response is documented.

Possible AIH (Below Threshold)

Patients scoring below the probable threshold require active investigation of alternative diagnoses. If clinical suspicion for AIH remains after comprehensive workup, options include additional serological testing (anti-SLA/LP, pANCA), repeat liver biopsy, the simplified IAIHG score, or a carefully monitored therapeutic trial with serial biochemical assessment. Some patients with scores just below the threshold may still have AIH, particularly if individual parameter penalties (e.g., drug exposure, AMA positivity) are driving the low score despite otherwise typical features.

Monitoring and Recalculation

The revised scoring system is not designed for serial monitoring of disease activity. Once a diagnosis of AIH is established (or excluded), ongoing management relies on standard biochemical markers (AST, ALT, IgG) rather than repeated scoring. However, recalculation is valuable in specific scenarios:

• After a therapeutic trial: Switching from pre-treatment to post-treatment interpretation and adding treatment response points can clarify the diagnosis in patients who were initially classified as probable or possible.
• After autoantibody seroconversion: Some patients who are initially seronegative develop positive autoantibodies over time. Repeat serological testing 3 to 6 months after initial evaluation may yield new positive results that change the score.
• After new histological data: A repeat liver biopsy (e.g., obtained to assess fibrosis progression or treatment response) may reveal histological features that were not present or not identified on the initial biopsy.

Practical Considerations for Accurate Scoring

• Use IIF for autoantibody titers when possible. The scoring system's titer cutoffs were calibrated to IIF results. If only ELISA results are available, note this limitation when interpreting the score.
• Measure IgG directly, not by calculation. Direct nephelometric or turbidimetric IgG measurement is more accurate than calculating globulins from total protein minus albumin.
• Ensure comprehensive viral testing. The viral markers parameter requires testing for hepatitis A (IgM anti-HAV), hepatitis B (HBsAg, IgM anti-HBc at minimum), and hepatitis C (anti-HCV, HCV-RNA). Incomplete viral testing may lead to an incorrect assignment of +3 points for negative markers when a viral infection is actually present but untested.
• Request expert pathology review. The histological component is complex and consequential. Review by a hepatopathologist experienced in autoimmune liver diseases improves the accuracy of the histological assessment and, by extension, the composite score.
• Document the scoring rationale. Record which parameter values were used and any assumptions or limitations (e.g., ELISA-based autoantibody results, biopsy not available, drug history uncertain). This documentation supports clinical decision-making and enables accurate recalculation if new data become available.